The NADP can support you in finding project partners for projects aimed at the development of new antibiotics and alternative therapies (prevention and care) for human and animal health. You can contact NADP via [email protected] with your questions about matchmaking and opportunities for your own project.
Support researchers and SMEs to bring novel antibiotics and alternatives a step closer to the clinic.
Continuous application - check collection dates
Horizon2020 Work Programmes
Horizon 2020 is the financial instrument of the European Commission that aims to drive economic growth and create jobs. Within Horizon 2020, research and innovation are coupled with an emphasis on excellent science, industrial leadership and tackling societal challenges.
Health, demographic change and wellbeing: first stage 23 January 2019, second stage 4 September 2019
Food security, sustainable agriculture and forestry, marine, maritime and inland water research and the bioeconomy: first stage 13 February 2019, second stage 11 September 2019
Partnering with AMR Centre (U.K.)
AMR Centre’s accelerates the development of new antimicrobial drugs and diagnostics. As such the AMR Centre works globally with companies and research institutions to support the development of their products from lead optimization through to Phase 2A. The AMR Centre aims to progress circa 5 new projects each year.
Novartis Venture Fund
The Novartis Venture Fund makes equity investments in life science companies focussing on the development of novel therapeutics and platforms. Investments by the Novartis Venture Fund are made as equity participation typically as the lead or co-lead investor in a syndicate with a board seat. The Novartis Venture Fund has a relatively high amount of investments in the domain of infectious diseases.
Strategic actions on product-related implementation research 2019
The purpose of this call for proposals is to support distinct strategic actions to translate medical interventions of proven efficacy (diagnostics, drugs, vaccines, and microbicides) into routine care. Proposals may include testing of delivery methods to increase population coverage, retention in care and adherence to the intervention. We believe that this specific opportunity is a particularly nice fit with the mission from AMR Global.
Pre-applications are expected by 10 October 2019
New drugs and vaccines for priority pathogens in antimicrobial resistance 2019
The purpose of this call for proposals is to provide funding for clinical trials to be conducted in sub-Saharan Africa which aim to develop new or improved medicinal products (drugs and vaccines) or combinations thereof against pathogens from the WHO priority list that also fall within the scope of the EDCTP2 programme, specifically Campylobacter, Salmonella, Streptococcus pneumoniae, and Mycobacterium tuberculosis.
Pre-applications are expected by 7 November 2019
New diagnostics (critical pathogens)
CARB-X will fund Feasibility Demonstration, Optimization & Prep for Development and Product Development stages as well as the System Integration and Testing stage of new diagnostics. Note that CARB-X can support products under development in academic or non-commercial drug development centers, but organizations with a track record of transitioning products from pre-clinical development to clinical research are of particular interest. Furthermore note that 10/20% co-funding is required.
Pre-applications are expected before August 19th
Antibiotic Resistance (ABR)
This is a call for submission of project ideas addressing the reduction of the antibiotic resistance burden. Reuse of existing data, improvement of the quality and sustainability of this data, implementation and impact and implementation failure are part of this call.
Pre-applications are expected before September 10th